ERBB3 and non-small cell lung carcinoma: However, the crucial finding of this study was the demonstration of the efficacy of a novel treatment combination strategy in NSCLC models, based on the use of a HDACi, plus an anti-ErbB3 MoAb such as A3, previously generated by our group [9, 23].